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T0001 is the first mutant of etanercept with a higher affinity to tumor necrosis factor α (TNF-α) 
than etanercept. In order to investigate the safety and tolerability of T0001, a study was carried 
out in healthy Chinese subjects. A first-in-human, dose escalation study was conducted in healthy 
Chinese subjects. Fifty-six subjects were divided into six dose cohorts (10 mg, 20 mg, 35 mg, 50 
mg, 65 mg and 75 mg) to receive a single subcutaneous injection of T0001. Safety and tolerability 
assessment were based on the records of vital signs, physical examinations, clinical laboratory tests, 
12-lead electrocardiograms and adverse events (AEs). All subjects were in good compliance and 
none withdraw due to AEs. No serious AEs occurred. A total of twenty-three AEs in sixteen subjects 
were recorded, and eighteen of these AEs were believed to be related to T0001. The most frequently 
reported AEs were injection site reactions and white blood cell count increase. All these AEs were of 
mild to moderate intensity and most of them recovered spontaneously within 14 days. In this study, no 
dose-limiting toxicity was observed, and the maximum tolerated dose was identified as 75 mg. T0001 
was considered safe and generally well tolerated at doses up to 75 mg in healthy Chinese volunteers. 
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory 
polyarthritis with high morbidity (Sanmartí, Ruiz-
Esquide, Hernández, 2013). This disorder affects 0.5% 
to 1.0% of adults around the world (Josef, Daniel, Iain, 
2016). However, the prevalence of RA ranges from 0.2% 
to 0.37% in mainland China, which is similar to that 
in most Asian and South American countries (Zeng 
et al., 2008). Research suggests that overproduction 
of tumor necrosis factor α (TNF-α) can lead to RA 
(Bazzoni, Beutler, 1996). Therefore, many guidelines 
recommend TNF-α inhibitors to active RA patients who 
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have dissatisfactory responses to conventional disease-
modifying anti-rheumatic drugs (Singh et al., 2016).
Etanercept, a TNF receptor 2-Fc fusion protein 
(TNFR2-Fc) acting as a TNF-α inhibitor (Enbrel®, 
Amgen and Wyeth), has been available for clinical 
use in the US since late 1998 (Goffe, Cather, 2003). 
However, 25% to 38% of patients display poor responses 
to etanercept (Alonso-Ruiz et al., 2008), which is 
partly due to insufficient etanercept affinity to TNF-α. 
Therefore, enhancing etanercept affinity may contribute 
to efficacy improvement and dose reduction. 
T0001, the first mutant of etanercept, is a 
recombinant human TNFR-Fc fusion protein mutant 
(rhTNFR (m): Fc) which has been developed by 
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co. 
Ltd (China). Preclinical studies showed that T0001 had 
a 1.5-fold higher bioactivity to block TNF-α in vitro 
and a 3.65-fold higher constant value than etanercept. 
Moreover, it can significantly improve responses in rat 
arthritis models induced by collagen (Yang et al., 2010). 
In addition, T0001 could induce apoptosis, which had 
a potential treatment capability in Crohn’s disease and 
ulcerative colitis (Shen et al., 2017). T0001 has been 
registered patent (Liu et al., 2009). 
The structure of T0001 is similar to etanercept. 
However, mutation of two amino acid sites may change 
the safety and tolerability of T0001 in human body. A 
study has already demonstrated that T0001 was absorbed 




0-∞ values compared to etanercept (Wang et al., 
2017). These results indicated that T0001 had greater 
exposure and longer retention than etanercept in human 
body. Nevertheless, whether this high-affinity variant 
can be used in human safely was still unverified. A first-
in-human study was therefore carried out to evaluate the 
safety and tolerability of T0001. 
MATERIAL AND METHODS
Study drug and administration
The study drug T0001 (batch number: 20130403) 
was provided by Shanghai Fudan-zhangjiang Bio-
Pharmaceutical Co. Ltd (China). The drug was delivered 
as 0.6 mL prefilled syringes, each containing 30 mg 
active rhTNFR (m): Fc. All the drug should be stored 
in a refrigerated unit at 2 °C to 8 °C in the dark. T0001 
was administrated by subcutaneous (SC) injection in 
the abdomen. 
Study subjects 
Fifty-six healthy Chinese subjects were required 
in this study. Only subjects who met all the inclusion 
criteria and not the exclusion criteria were eligible. 
Inclusion criteria for this study were Chinese 
healthy subjects (1) aged from 18 to 45; (2) with a 
body mass index between 19 and 24 kg m-2; and (3) 
with normal clinical findings for vital signs (including 
blood pressure, temperature, heart rate and respiratory 
rate), physical examination, clinical laboratory tests 
(hematology, blood biochemistry, urinalysis and stool 
routine) and 12-lead electrocardiogram (ECG).
Exclusion criteria consisted of subjects who (1) 
were treated with any biological agents previously; (2) 
had a history of allergic or hypersensitivity to rhTNFR: 
Fc components; (3) had history or strong evidences of 
the respiratory, cardiovascular, renal, gastrointestinal, 
hepatic, endocrine, hematologic, neurologic or 
psychiatric systems abnormalities; (4) had abnormal 
values of blood biochemistry and hematology test; 
(5) had evidences of active or latent tuberculosis or 
infections; (6) participated in other clinical trials within 
three months; (7) donated blood within three months; (8) 
had records of drug or alcohol abuse; (9) were positive 
for anti-drug antibody, anti-nuclear antibody, double-
stranded DNA, extractable nuclear antigen, hepatitis 
B virus surface antigens, hepatitis C virus, HIV or 
syphilis antibodies. Female subjects who were pregnant 
or lactating were also excluded.
Study design 
The study was conducted at Peking University 
People’s Hospital (Clinical Trials. Gov. Identifier: 
NCT02291471) in accordance with the principles of the 
Declaration of Helsinki (World Medical Association, 
2003), the Guidance for Good Clinical Practice (State 
Food and Drug Administration of China, 2003) and 
other applicable regulatory requirements. The study 
protocol, protocol amendments, and consent form were 
approved by the Ethics Committee of Peking University 
People’s Hospital (Approval No. 2014PHA015-01). 
Informed consents were obtained from all subjects 
included in the study.
The initial dose of this trail was formulated with the 
results of preclinical toxicology tests (Tong Y, Zheng 
W, Fang W, unpublished results). In acute toxicity 
test, the no observed adverse effect level (NOAEL) 
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of cynomolgus was greater than 240 mg/kg after SC 
injection of T0001. In long-term toxicity test, NOAEL 
of rats and cynomolgus were 120 mg/kg and 60 mg/kg 
respectively. The minimum human equivalent dose 
(HED) was calculated to be 21 mg/kg based on the 
NOAEL value of rat in long-term toxicity tests [HED 
(mg/kg) = animal NOAEL (mg/kg) × (animal weight 
in kg/human weight in kg) 0.33]. The safety factor 
(SF) was selected as 10 to increase assurance, then the 
maximum recommended starting dose (MRSD) was 
calculated as 126 mg [MRSD (mg/kg) = HED (mg/kg) 
÷ SF, supposing human weight was 60 kg]. However, 
the pharmacologically active dose (PAD) may be a 
more sensitive toxicity indicator than NOAEL because 
toxicity could arise from exaggerated pharmacologic 
effects in biologics. The PAD of T0001 was calculated 
as 1 mg/kg in the adjuvant arthritis model of rats 
and the rheumatoid arthritis model induced by type 
II collagen. The HED was therefore calculated as 9.8 
mg by the PAD [HED (mg/kg) = animal PAD (mg/
kg) × (animal weight in kg/human weight in kg) 0.33, 
supposing human weight was 60 kg] (State Food and 
Drug Administration of China, 2012). The initial 
dose was set as 10 mg by combining the results of 
these two methods and the dosage of similar drugs. 
The long-term toxicity test of rats indicated that the 
maximum tolerated dose (MTD) was 120 mg/kg. The 
MTD of human, which was 1/5 - 1/2 MTD of animal 
long-term toxicity test, can yield up to 1440 mg (Food 
and Drug Administration, 2010). Considering the 
clinical actual needs and the effective dose of similar 
drugs, the maximum dose was set as 75 mg. The 
dose increments were in accordance with a modified 
Fibonacci sequence as following: 2.00, 1.67, 1.50, 
and 1.30 for the subsequent two dose levels (Penel, 
Kramar, 2012). Thus the doses were selected as 10 
mg, 20 mg, 35 mg, 50 mg, 65 mg and 75 mg. Fifty-
six subjects were randomly assigned to these six dose 
cohorts (six in 10 mg cohort and ten in other cohorts). 
Doses were administered in a serial manner which 
proceeded from the lowest to the highest, and safety 
should be confirmed before each dose increase. 
All eligible subjects checked into the Phase I 
Clinical Research Unit of Peking University People’s 
Hospital with unified accommodation and standard food. 
At 8:00 am on day 1, all the subjects were administered 
a single SC injection of T0001. Consumption of food 
within four hours or water intake within two hours 
was avoided after drug administration. All subjects 
were continuously observed for 96 hours in the ward 
and 35 days after discharge. To assess drug safety and 
tolerability, all subjects were closely monitored for 
clinically significant findings. Vital signs and physical 
examination were checked 1 h before dosing and 2 
h, 12 h, 24 h after injection. Hematology, C-reactive 
protein (CRP) and ECG were measured 12 h, 24 h after 
injection. Further follow-ups were conducted on days 
3, 14, 21 for the aforementioned tests and other clinical 
laboratory tests (blood biochemistry, urinalysis, stool 
routine and erythrocyte sedimentation rate). Adverse 
events (AEs) and serious AEs were monitored and 
recorded throughout the study. 
The study would be terminated if any serious 
AEs occur, or over half of the subjects experience 
AEs of grade II or greater according to the Common 
Terminology Criteria for Adverse Events Version 4.0 
(US Department of Health and Human Services, 2009). 
The records on AEs described the intensity, duration, 
outcome, seriousness and the relationship with the 
study drug.
Safety and tolerability assessment
The study diary of each subject was reviewed to 
ascertain compliance and help with AEs discussion 
after the study. Indicators for the safety assessment 
were based on physical examinations, vital signs, 
laboratory tests, 12-lead ECGs and local tolerability 
evaluations. Special attention was paid to the possibility 
of infectious diseases. The MTD was defined as the 
highest T0001 dose with acceptable side effects or 
dose-limiting toxicities (DLTs). DLTs were connected 
with the events related to the study drug, which were 
deemed grade II, grade III, or grade I persisting longer 
than two weeks. 
Statistical analyses
The demographic characteristic comparisons 
among the six treatment groups were performed using 
analysis of variance (ANOVA) with SAS version 9.3 
(SAS Institute Inc., Cary, USA). Statistical analyses of 
safety and tolerability for each cohort were performed 
using repeated measures of ANOVA; the level of 
significance was set at P < 0.05. Safety parameters were 
summarized with descriptive statistics, graphs and 
numerical tables as appropriate.
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RESULTS
Demographics and baseline characteristics
A total of fifty-six healthy volunteers were enrolled 
in the T0001 dose-escalation trial. The demographics 
and baseline characteristics of each group are listed in 
Table I. All subjects received their designated doses. 
No dose interruption, dose adjustment, dropout or 
discontinuation took place during the trial.
Safety and tolerability results
 All subjects were compliant. No serious AEs or 
unexpected AEs occurred and no subject withdrew due 
to AEs during the trial. Twenty-three AEs in sixteen 
subjects were observed. The incidences of AEs in 10 
mg, 20 mg, 35 mg, 50 mg, 65 mg and 75 mg cohorts were 
1.8%, 8.9%, 3.6%, 5.4%, 5.4% and 3.6%, respectively. 
The differences were not statistically significant (P = 
0.24, P > 0.05). Eighteen AEs were considered to be 
drug-related. The most frequently reported drug-related 
AEs were injection site reactions (4 cases; 7.1%) and 
white blood cell (WBC) count increase (3 cases; 5.4%) 
(Table II). The mean values of infection indicators, 
including WBC count, neutrophils count and CRP, 
were compared at each scheduled visit time (Figure 1). 
No statistically significant differences were found in 
these indicators among six dose groups over the study 
(P > 0.05). However, significant statistical differences 
occurred in WBC count (P = 0.007, P < 0.05) and 
neutrophils count (P = 0.000, P < 0.05) during different 
follow-ups within two days after T0001 administration. 
Nevertheless, no obvious trend were found. CRP 
during different follow-ups did not show any statistical 
differences (P > 0.05). 
















Male 3 5 5 5 5 5 --
Female 3 5 5 5 5 5 --
Age (year) 24.5 ± 2.6 25.4 ± 3.2 24.3 ± 3.3 24.4 ± 2.8 26.7 ± 3.1 24.4 ± 2.6 0.433
Height (cm) 167.6 ± 4.8 165.0 ± 7.3 165.3 ± 6.6 165.6 ± 10.7 170.7 ± 9.6 168.9 ± 11.2 0.662
Weight (kg) 60.4 ± 4.9 59.0 ± 7.7 58.5 ± 6.5 60.9 ± 9.5 63.6 ± 8.2 60.0 ± 7.4 0.562
BMI (kg/m2) 21.5 ± 1.3 21.6 ± 1.4 21.4 ± 1.6 22.1 ± 1.5 21.7 ± 1.2 21.0 ± 1.4 0.634
Values of age, height, weight and BMI are presented as the mean ± standard deviation (SD);
The number of male and female participants for each cohort is indicated;
BMI, body mass index.
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FIGURE 1 - Changes detection in the value of laboratory parameters after single dose subcutaneous administration of T0001 in 
healthy subjects in each of the follow-up period (day 0, day 1, day 2, day 3, day 14 and day 21). (A). WBC count; (B.) Neutrophil 
count; (C). CRP; WBC = white blood cell, CRP = C-reactive protein.
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The severity of all reported AEs was mild, with the 
exception of three moderate AEs in the 10 mg, 20 mg and 
75 mg groups. Two of these three AEs, upper respiratory 
tract infection (in 10 mg cohort) and oral infection (in 
75 mg cohort), were reckoned as infection which were 
related to T0001. Both subjects recovered from infection 
after receiving 0.4 mg levofloxacin mesylate tablets for 
three days. The other moderately severe AE was WBC 
count decreased to 2.89 × 109 L-1 in 20 mg cohort on day 
21 after T0001 administration. The decrease returned 
to normal 7 days later (normal range: 3.5–9.5 × 109 
L-1, details are showed in supplementary information). 
The relationship between this AE and T0001 treatment 
was hard to ascertain yet. All other drug-related AEs 
resolved spontaneously within 14 days. None of these 
events required additional medical treatments or had 
any impacts in the study. No DLT was observed even 
in the highest dose cohort. Therefore, the MTD was 
identified as 75 mg in this trial.
Moreover, safety comparison between genders was 
conducted since gender ratio of subjects in the study 
was 1: 1. However, no gender difference was found in 


















AEs (%) 1 (1.8) 5 (8.9) 2 (3.6) 3 (5.4) 3 (5.4) 2 (3.6) 16 (28.7)
Drug-related AEs (%) 1 (1.8) 5 (8.9) 1 (1.8) 2 (3.6) 3 (5.4) 2 (3.6) 14 (25.0)
Injection site reaction 0 3 0 1 0 0 4 
White Blood cell count increased 0 0 1 0 2 0 3
Oral infection 0 0 0 0 0 1 1 
Upper respiratory tract infection 1 0 0 0 0 0 1 
White Blood cell 
count decreased
0 1 0 0 0 1 2 
Erythrocyte sedimentation 
rate increased
0 2 0 0 0 0 2 
Plasma uric acid increased 0 1 0 0 1 0 2 
Conjugated bilirubin increased 0 1 0 0 0 0 1 
Human chorionic 
gonadotrophin increased
0 0 0 1 0 0 1 
Neutrophilic granulocye 
count increased
0 0 1 0 0 0 1 
Hemobilirubin increased 0 1 0 0 0 0 1 
Epigastric discomfort 0 0 0 1 0 0 1 
Data are presented as the number of AEs; N is the total number of subjects studied and n is the number of subjects in each 
cohort.
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that the AE incidences were similar in male and female 
subjects (male AE % = 43.75%).
DISCUSSION
This was the first study to investigate the safety and 
tolerability of T0001 in human body. All the six dose 
escalation cohorts displayed good safety and tolerability 
after SC injection of T0001. No significant difference 
occurred in different groups and genders. 
Nevertheless, the two AEs of WBC count decrease 
were unexpected in this study, one of which occurred in 
20 mg cohort on day 21 and the other in 75 mg cohort 
on day 14. Both AEs were spontaneously stabilized to 
normal within 7 days. A previous study demonstrated that 
the half-life of T0001 was 42.1–58.2 h and single use of 
T0001 almost completely metabolized after five half-lives 
(Wang et al., 2017). Therefore, the AE occurred 21 days 
after T0001 administration may be unrelated to the study 
drug. However, the AE reported on day 14 was considered 
to be T0001-related. Significant hematological disorders 
with serious complications, in particular leukopenia 
and neutropenia, have been reported in patients treated 
with etanercept or other TNF-α inhibitors for many 
times (Wenham, Gadsby, Deighton, 2008; Azevedo 
et al., 2012; Haroon, Daly, Harney, 2012). A post-
marketing study showed that 3.2% of patients developed 
a hematological AE after receiving etanercept (Feltelius 
et al., 2005). The British Society for Rheumatology has 
updated their guidelines to monitor complete blood cell 
count regularly in patients on anti-TNF therapies in 2010 
(Ding et al., 2010). Nevertheless, as far as we know, 
other guidelines have not yet been implemented. TNF-α 
is part of a complex network of cytokines that controls 
hematopoiesis, but the pathogenesis of the observed 
blood abnormalities is still unknown (Bessissow et 
al., 2012). On the one hand, TNF-α can elicit either a 
stimulatory or an inhibitory effect on the in vitro growth 
of hematopoietic progenitors (Jacobsen et al., 1994). 
On the other hand, TNF-α regulates the granulocyte 
macrophage colony-stimulating factor and several pro-
inflammatory cytokines, such as IL-1, IL-6 and IL-8. It 
is, therefore, speculated that anti-TNF-therapy can induce 
bone marrow failure by blocking stem cell differentiation 
theoretically (Keystone, 2001).
The clinical safety results of etanercept, which 
supported the initial RA indication approvals, were 
involved to compare safety results with T0001 (European 
Medicines Agency, 2004). The most frequently reported 
AEs in etanercept-treated patients were injection site 
reactions (42%) and infections (58%). Other AEs 
included headache (17%), rhinitis (13%), rash (13%), 
nausea (12%), abdominal pain (9%), asthenia (7%), 
pharyngitis (7%) and back pain (5%). No complaints 
of headache, rhinitis and pharyngitis were recorded in 
T0001, implying that mutations of the two amino acid 
sites may reduce the likelihood of these AEs. However, 
differences in study design and subject status should be 
taken into account. Further clinical trials of T0001 with 
more subjects and longer follow-up periods are definitely 
needed in the future. 
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